Authors must give the consent form for publication of photographs of identifiable patients. Authors can refer to the consent form on the website of Ann Dermatol.

Authors are responsible for disclosing all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist currently and over the past 3 years. These include but are not limited to consultant arrangements, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing the study, and consulting relationships with investment companies. Completed 'conflict of interest' form should be submitted in the process of manuscript submission.

All sources of funding should be declared as an acknowledgment at the end of the manuscript. Information on the funding source (including grant identification, if available) must also be completed. Authors must describe the role of the study sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source had no such involvement, the authors should so state.

Ann Dermatol follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals by the International Committee of Medical Journal Editors (ICMJE, http://www.icmje.org) and the Good Publication Practice Guidelines for Medical Journals 3rd by the Korean Association of Medical Journal Editors(KAMJE, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=13). All persons designated as authors should be qualified for authorship, and those who are qualified should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, that is from inception to published article. Authorship credit should be based only on 1) substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2) drafting the work or revising it critically for important intellectual content; 3) final approval of the version to be published; 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Conditions 1, 2, 3 and 4 must all be met. The corresponding author is primarily responsible for all issues to the editor and audience. A corresponding author should be designated when there are two or more authors. When a large, multicenter group conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors and the group name. Journals generally list in the Acknowledgments, other members of the group who were involved in the acquisition of funding, collection of data, or general supervision of the research group. Acquisition of funding, collection of data, or general supervision of the research group, by themselves, does not justify authorship. All others who contributed to the work who are not authors should be named in the ACKNOWLEDGMENT section. After publication, Ann Dermatol does not correct authorship unless any mistake has been made by the editorial side.

At submission, authors must disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the production of submitted work. Use of AI for writing assistance should be reported in the acknowledgment section. Authors who use such technology should describe, in both the cover letter and the submitted work, how they used it. Annals of Dermatology follows ICMJE’s policy that artificial intelligence (AI) tools, such as ChatGPT, cannot be a named author because they cannot be responsible for the accuracy, integrity, and originality of the work, and these responsibilities are required for authorship. Therefore, humans are responsible for any submitted material that included the use of AI-assisted technologies. Authors should carefully review and edit the result because AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Authors should not list AI and AI-assisted technologies as an author or co-author, nor cite AI as an author. Authors should be able to assert that there is no plagiarism in their paper, including in text and images produced by the AI. Humans must ensure there is appropriate attribution of all quoted material, including full citations.

A clinical trial, defined as “any research project that prospectively assigns human subjects to intervention and control groups to study the cause-and-effect relationship between a medical intervention and a health outcome,” should be registered to the primary registry prior to publication. Ann Dermatol accepts the registration in one of the primary registries that participate in the WHO International Clinical Trials Portal (http://www.who.int/ictrp/en/), NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/), ISRCTN Registry (www.ISRCTN.org), or the Clinical Research Information Service (CRIS), Korea CDC (https://cris.nih.go.kr/cris/index/index.do). The clinical trial registration number should be written at the end of the abstract.

Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s).” Characteristics of reports that are substantially similar include the following: (a) “at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication),” (b) “the subjects or study populations are the same or overlapped,” (c) “the methodology is typically identical or nearly so,” and (d) “the results and interpretation have little or no variations.” When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other already published material or material being evaluated for publication and should also state how the manuscript submitted to Ann Dermatol differs substantially from this other material. If all or part of the patient population was previously reported, this should be mentioned in the Materials and Methods section, with citations of the appropriate reference(s).

All authors of accepted manuscripts must sign a copy of the Journal's “Authorship Responsibility and License Agreement” form and submit it to Fax: no. +82-2-3472-4203 or e-mail it to dermajournal@anndermatol.org. For the copyrights of the contributions published in Ann Dermatol (see Creative Commons; Attribution-Noncommercial) at http://creativecommons.org.

If any portion of a manuscript has been previously published, the original source must be acknowledged, and the written permission from the copyright holder to reproduce the material must be submitted.

Ann Dermatol and the publisher are not responsible for statements made by any contributor. Authors are responsible for all statements made in the text, including the editorial changes approved by the author. Authors should retain copies of all submitted materials.